Rgenix

Developing innovative therapies for cancer patients using technology from Rockefeller University.

Investment

The Partnership Fund and the state’s Innovate NY program invested in this early-stage life science company as part of its efforts to grow life sciences in New York.

About

Spun out of Dr. Masoud Tavazoie’s lab at Rockefeller University, Rgenix is a clinical-stage biopharmaceutical company developing first-in-class drug candidates that target key cancer pathways. Their lead cancer drug candidate targets the immune system to block cancer progression.

Visit site